Fig. 2From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemiaPFS of the different EOT CD4 levels and according to IGHV mutational status in the whole population. (A) PFS curves according to EOT CD4 status in the whole population (p = 0.0016). (B) PFS curves according to EOT CD4 status in patients with IGHV-unmutated status (p < 0.0001) (C) PFS curves according to EOT CD4 status in patients with mutated IGHV (p = 0.0576)Back to article page